Changeflow GovPing Healthcare & Life Sciences EP4153578A1 - Chromen-4-one Derivatives (Flavon...
Routine Rule Added Final

EP4153578A1 - Chromen-4-one Derivatives (Flavones) as CK2 Inhibitors for Neuroinflammation - Salk Institute

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The EPO published patent application EP4153578A1 on April 15, 2026, covering chromen-4-one derivatives such as flavones for use as casein kinase 2 (CK2) inhibitors in the treatment of neuroinflammation. The applicant is the Salk Institute for Biological Studies, with inventors Ioana I. Nitulescu, Fred H. Gage, and James K. Tucker. The application is classified under IPC subclasses C07D 311/22, C07D 311/28, and multiple other organic chemistry codes, with pharmaceutical composition claims under A61K 31/352 and A61K 31/443.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.

What changed

The EPO published patent application EP4153578A1 on April 15, 2026, covering chromen-4-one derivatives (including flavones) for use as casein kinase 2 (CK2) inhibitors in treating neuroinflammation. The application names the Salk Institute for Biological Studies as applicant and Ioana I. Nitulescu, Fred H. Gage, and James K. Tucker as inventors. IPC classifications span C07D organic chemistry subclasses and A61K pharmaceutical composition subclasses. Designated states cover 29 European jurisdictions including all EU member states.\n\nPharmaceutical companies and researchers developing kinase-inhibitor therapies for neuroinflammatory conditions should review the scope of the claims to assess potential freedom-to-operate considerations. The patent's publication establishes a priority date and makes the technical disclosure publicly available, which may inform future R&D strategy in CK2-inhibition space.

Archived snapshot

Apr 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

CHROMEN-4-ONE DERIVATIVES, SUCH AS E.G. FLAVONES, FOR USE AS CK2 INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATION

Publication EP4153578A1 Kind: A1 Apr 15, 2026

Applicants

Salk Institute for Biological Studies

Inventors

NITULESCU, Ioana I., GAGE, Fred H., TUCKER, James K.

IPC Classifications

C07D 311/22 20060101AFI20211126BHEP C07D 311/28 20060101ALI20211126BHEP C07D 405/04 20060101ALI20211126BHEP C07D 413/04 20060101ALI20211126BHEP C07D 405/12 20060101ALI20211126BHEP C07D 413/12 20060101ALI20211126BHEP C07D 407/04 20060101ALI20211126BHEP C07D 471/04 20060101ALI20211126BHEP C07D 498/04 20060101ALI20211126BHEP C07D 407/06 20060101ALI20211126BHEP C07D 401/10 20060101ALI20211126BHEP C07D 417/14 20060101ALI20211126BHEP C07D 405/14 20060101ALI20211126BHEP A61K 31/352 20060101ALI20211126BHEP A61K 31/443 20060101ALI20211126BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Research institutions
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent publication Pharmaceutical compounds Kinase inhibitor research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!